UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1327, 2026

BARINTHUS BIOTHERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

England and Wales	001-40367	Not Applicable	~~001-40367~~	~~Not Applicable~~
(State or other jurisdictionof incorporation)			(CommissionFile Number)	(I.R.S. EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Barinthus Biotherapeutics plc

20400 Century Blvd, Suite 210,

Germantown, MD 20874

(Address of principal executive offices, including zip code)

443 917-0966

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered	~~Trade Symbol(s)~~	~~Name of each exchange on whichregistered~~
American Depositary Shares	BRNS	The Nasdaq Global Market	~~BRNS~~	~~The Nasdaq Global Market~~
Ordinary shares, nominal value £0.000025 per share*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ¨

* American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

~~Item 2.02. Results of Operations and Financial Condition.~~00-0000000

OnItem ~~March 13,~~5.02. ~~2026,~~Departure ~~Barinthus~~of ~~Biotherapeutics~~Directors ~~plc~~or ~~(the~~Certain ~~“Company”)~~Officers; ~~provided~~Election ~~an overview~~ of ~~the~~Directors; ~~Company’s~~Appointment ~~progress~~of ~~and~~Certain ~~announced~~Officers; ~~its~~Compensatory ~~financial~~Arrangements ~~results for the year ended December 31, 2025. The full text~~ of ~~the~~Certain ~~press release issued in connection with the update is furnished as Exhibit 99~~Officers.~~1 to this Current Report on Form 8-K.~~

~~The~~As ~~information~~previously indisclosed, ~~Item~~Gemma ~~2.02~~Jones ofprovides ~~this~~services ~~Form~~to ~~8-K~~Barinthus Biotherapeutics plc (~~including~~the ~~Exhibit 99.1) shall not be deemed~~ “~~filed~~Company”) as ~~for~~an ~~purposes~~employee of ~~Section~~CFGI 18and ofserves as the ~~Securities~~Company’s ~~Exchange~~principal ~~Act~~accounting ofofficer. On ~~1934~~March 27, ~~as amended (the “Exchange Act”)~~2026, orMs. Jones ~~otherwise~~notified ~~subject to~~ the ~~liabilities~~Company of that ~~section,~~she ~~nor~~will ~~shall~~step itdown beas ~~deemed incorporated by reference in any filing under~~ the ~~Securities~~Company’s ~~Act~~principal ofaccounting ~~1933~~officer, effective as ~~amended~~of ~~(the "Securities Act")~~April 30, ~~or the Exchange Act, except as expressly set forth by specific reference in such a filing~~2026.

~~Item~~Forward ~~7.01~~Looking ~~Regulation FD Disclosure.~~Statements

OnThis ~~March~~Current ~~13,~~Report ~~2026~~on Form 8-K contains forward-looking statements, within the ~~Company~~meaning ~~updated~~of ~~its~~the ~~corporate~~Private ~~presentation~~Securities ~~for~~Litigation ~~use~~Reform inAct ~~meetings~~of ~~with~~1995, ~~investors~~as amended, ~~analysts~~which can generally be identified as such by use of the words “expect,” “will,” and ~~others~~similar expressions, although not all forward-looking statements contain these identifying words. AThese ~~copy~~forward-looking statements include, without limitation, express or implied statements regarding the intended departure of ~~this~~the ~~presentation~~Company’s isprincipal ~~furnished~~accounting asofficer ~~Exhibit~~and 99the timing thereof.2 Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K, including, without limitation, risks and uncertainties related to the success, cost and timing of the Company’s pipeline development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, the risk that the Company may not achieve the anticipated benefits of its pipeline prioritization and corporate restructuring, the Company’s ability to fund its operations and access capital, the Company’s preliminary estimates of its cash and cash equivalents, including the risk that final financial results may differ materially from the Company’s preliminary estimates, and other risks identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Reports on Form 10-Q and subsequent filings with the SEC. The Company ~~undertakes~~cautions noyou not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, ~~supplement~~conditions or ~~amend~~circumstances on which any such statements may be based, or that may affect the ~~presentation~~likelihood that actual results will differ from those set forth in the forward-looking statements.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.SIGNATURE

~~Additional~~Pursuant ~~Information~~to ~~and~~the ~~Where~~requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to ~~Find~~be Itsigned on its behalf by the undersigned hereunto duly authorized.

In connection with the proposed transaction, the combined company plans to file with the Securities and Exchange Commission (the “SEC”) and mail or otherwise provide to Company’s investors and security holders a registration statement on Form S-4 that will contain a joint proxy statement/prospectus (the “Registration Statement”). THE COMPANY’S INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE REGISTRATION STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY THE COMPANY WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION.

	Barinthus Biotherapeutics plc

Date: March 31, 2026	By:	/s/ William Enright
		William Enright
		Chief Executive Officer

Investors and security holders may obtain a free copy of the Registration Statement and other documents that the combined company files with the SEC (when available) from the SEC’s website at www.sec.gov or at investors.barinthusbio.com.

Participants in the Solicitation

Clywedog Therapeutics Inc. (“Clywedog”), the Company and their respective directors, executive officers, other members of management, certain employees and other persons may be deemed to be participants in the solicitation of proxies from the security holders of the Company in connection with the proposed transaction. Security holders may obtain information

regarding the names, affiliations and interests of the Company’s directors and executive officers in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on March 13, 2026. To the extent holdings of the Company’s securities by the Company’s directors and executive officers have changed since the amounts set forth in such Annual Report on Form 10-K, such changes have been or will be reflected on subsequent Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed transaction will be included in the Registration Statement relating to the proposed transaction when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov and the Company’s website at investors.barinthusbio.com.

No Offer or Solicitation

This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

99.1			Press Release dated March 13, 2026.
99.2			Corporate Deck dated March 2026.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Barinthus Biotherapeutics plc
Date: March 13, 2026	By:	/s/ William Enright
		William Enright
		Chief Executive Officer

Filing Compare · Barinthus Biotherapeutics plc.